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Differentiating Between Lactose
Intolerance, Celiac Disease, and Irritable
Bowel Syndrome-Diarrhea
Karlen E. Luthy, DNP, FNP, Sophia G. Larimer, MS, FNP, and
Donna S. Freeborn, PhD, FNP
ABSTRACT

The purpose of this article is to assist nurse practitioners (NPs) and other primary care
providers in differentiating between lactose intolerance, celiac disease, and diarrheapredominant irritable bowel syndrome in adults. Based on subtle characteristics
gathered from the history and physical examination, the NP’s examination and
approach to testing will help distinguish between the 3 conditions. NPs should use a
sequential process of examination and testing to distinguish gastrointestinal disorders
that share common symptoms. A best practice algorithm is provided.
Keywords: abdominal pain, celiac disease, diagnosis, irritable bowel syndrome, lactose
intolerance
Ó 2017 Elsevier Inc. All rights reserved.

INTRODUCTION

G

astrointestinal (GI) disorders are frequently
seen in primary care settings and commonly
include lactose intolerance (LI), celiac disease (CD), and irritable bowel syndrome (IBS).
However, these disorders are often difﬁcult to
differentiate because each condition shares common
symptoms, which can contribute to delay in diagnosis. In fact, it takes approximately 1 year for patients with CD to be diagnosed after GI symptoms
appear.1 Likewise, 10%-15% of the population in the
United States is affected by IBS, but only 5%-7% are
actually diagnosed,2 and usually only after their
primary care provider has referred them to a
gastroenterologist.3
Abdominal complaints are commonly seen in the
primary care setting; therefore, nurse practitioners
(NPs) must be well versed in GI-related disorders and
utilize evidence-based information to work through
various differential diagnoses. Although LI, CD, and
IBS may present with similar symptoms, the pathology
differs. Unlike primary LI and IBS-D, which mainly
cause symptoms without mucosal inﬂammation, if CD
is not properly diagnosed, GI mucosal inﬂammation
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will continue, which may result in poor growth,
nutritional deﬁciencies, and other further complications. According to Pironti et al,4 among patients
complaining of chronic diarrhea and/or abdominal
pain, 81% have microscopic histologic damage due to
an underlying pathologic process. Therefore, it is
imperative that NPs use the most current information
to make accurate and timely diagnoses to prevent
pathologic disease processes from ensuing and to
improve the patient’s quality of life.5,6 Accordingly,
the purpose of this article is to introduce NPs to a
systematic evidence-based approach for successfully
differentiating LI, CD, and IBS in adults.
BACKGROUND INFORMATION ON LI, CD, AND IBS
Lactose Intolerance

LI is the most common metabolic food sensitivity,
affecting 60%-70% of people worldwide.7,8
Inadequate levels of the lactase enzyme result in
abdominal discomfort, bloating, gas, and diarrhea,
because undigested lactose in the colon is fermented
by bacteria.7,9 Primary lactose deﬁciency is the most
common cause of LI and is found most frequently in
South America, Africa, Asia, and descendants from
Volume 13, Issue 5, May 2017

those areas. Secondary lactose deﬁciency results from
injury and inﬂammation of the brush border of the
small intestine, such as can be found in Crohn’s
disease, and can also be caused by bacterial
overgrowth, gastroenteritis, CD, and disorders that
cause rapid GI motility.7,10
LI usually begins in childhood, but it is most
prevalent in adulthood, because the lactase enzyme
progressively decreases over the lifespan.8,9,11 About
two thirds of people in the world do not carry the
genetic makeup that allows for lactase production,
and are therefore either lactase persistent or
nonpersistent.12
Celiac Disease

CD is a genetically or autoimmune-based chronic
enteropathy of the small intestine that is caused by an
intolerance to gluten.5 Gluten is a complex of watersoluble protein that is a component in wheat, barley,
bulgur, durum, rye, and spelt.5 People who have the
genetic predisposition for CD typically carry the
human leukocyte antigen (HLA)-DQ2 or HLADQ8 genes (90% and 10%, respectively).5,6 Patients
with genetic-based and autoimmune diseases
(especially Turner’s syndrome, Down’s syndrome,
type I diabetes mellitus, and thyroid disease), as well
as ﬁrst-degree relatives of patients with CD, are
considered to be high risk for developing CD.5,6 An
autoimmune process proceeds when class II HLAs
produce autoantibodies against the enzyme tissue
transglutaminase (tTG) in the presence of gluten,
damaging the small intestine and altering the
environment in which nutrients are absorbed.5 Although
many patients can be managed simply by excluding
gluten from the diet, a few patients may require more
aggressive treatment with immunomodulatory
medications.3
CD involves a variety of symptoms with both GI
and systemic manifestations, usually lasting longer
than 3 months. A patient typically presents with
diarrhea, unexplained weight loss, abdominal
distention, bloating, dyspepsia, and ﬂatulence.5 It is
not uncommon for pain to be speciﬁcally located in
the right lower abdomen, and even accompanied by
a palpable mass, raising suspicions of appendicitis or
Crohn’s disease.13 Systemic manifestations of CD
include migraines, chronic fatigue, depression,
www.npjournal.org

irritability, Duhring’s dermatitis herpetiformis,
oral aphthous ulcers, loss of dental enamel, irondeﬁciency anemia, anorexia, osteoporosis, joint
pain, growth failure, short stature, delayed puberty,
amenorrhea, early menopause, reduced fertility, and
epilepsy.6,9,14 In addition to systemic manifestations,
patients with CD also have a 3-fold increased risk of
non-Hodgkin’s lymphoma.6
Irritable Bowel Syndrome

IBS affects 10%-15% of the world’s population and
is a set of GI symptoms resulting from irregular
relaxation and contraction of the bowel.2 The
idea that there may be a connection between
excessive microﬂora in the gut, as well as excessive
inﬂammation and cytokine activity, is supported by
evidence.15 Basic risk factors for IBS include female
gender; being between 20 and 40 years old; and
having psychosocial issues, such as anxiety,
depression, personality disorders, and abuse.16 There
are 4 subtypes of IBS, but IBS with diarrhea (IBS-D)
is most often confused with CD and LI. Patients
with IBS-D typically report diarrhea and abdominal
cramping that mainly occurs in the mornings and
after meals. Other complaints include mucus in the
stool, fecal incontinence, feelings of incomplete
evacuation, and pain relieved by defecation.10,15
IBS-D does not cause permanent damage to the
colon or increase the risk for colorectal cancer,
although it does severely impact a patient’s quality of
life. There is a possibility that CD and IBS-D can
coexist, but there are conﬂicting results supporting
routine screening of these concurrently.3,17
CURRENT RECOMMENDATIONS FOR DIAGNOSING LI

According to the most current information, it is
sufﬁcient to diagnose a patient with LI if GI complaints resolve with a lactose-free diet for at least
2 weeks. However, if symptoms persist or if the patient is unsuccessful or refuses to adhere to a trial of
lactose elimination, he or she should undergo the
lactose hydrogen breath test (sensitivity [69%-100%]
and speciﬁcity [89%-100%]), which is noninvasive
and cost-effective. During the test, individuals are
given 2 g/kg of lactose and tested for hydrogen in
their breath at a fasting baseline and in 30-minute
intervals for 3 hours.8,10 False-positive results occur
The Journal for Nurse Practitioners - JNP
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with inadequate pretest fasting or recent smoking,
and false-negative results occur with antibiotic use,
diabetes, gastric-emptying issues, or underlying
pulmonary disorders, because these factors can affect
the amount of hydrogen levels detected in the breath
of patients.7 An alternative option to the lactose
hydrogen breath test is the lactose tolerance test,
although it has a lower sensitivity (77%-96%) and
speciﬁcity (76%-94%) and is less convenient for the
patient because it requires consecutive blood
sampling.11
A patient who has a negative lactose hydrogen
breath test or lactose tolerance test but continues to
display abnormal GI symptoms after consuming
lactose may opt to undergo genetic testing or a
biopsy-based lactose intolerance quick test, which has
a sensitivity, speciﬁcity, and positive predictive value
nearing 100%. The biopsy sample can be collected
during endoscopy; however, because of its high cost
and invasiveness, the NP should order endoscopy
conservatively. Although genetic testing of the C/C
(-13910) and T/C (-13910) genes is an alternative
option, it is also costly and should be utilized
conservatively.7,8,11
CURRENT RECOMMENDATIONS FOR DIAGNOSING CD
Serologic Testing

Diagnosis of CD ﬁrst begins with serologic screening
for antibodies.18 The ﬁrst-line serologic test is the
tissue transglutaminase antibody (IgA tTG), which
has high sensitivity (90%-98%) and speciﬁcity
(95%-97%), is inexpensive, reliable, and easy to
interpret. According to evidence-based information,
a “total IgA” level should be tested simultaneously,
because 2% of people with CD have an IgA deﬁciency and, therefore, may falsely test negative for
IgA tTG. Patients who have an IgA deﬁciency
should next be tested for the IgG anti-deaminated
gliadin peptide serum antibody and the IgG tissue
transglutaminase antibody (IgG tTG).5
It is imperative that patients are on a gluten-rich
diet at the time of lab work because the absence of
gluten in the diet may result in a false-negative test.
Patients who cannot commit to eating a gluten-rich
diet prior to CD testing may have false-negative tests,
but can be screened via the IgA tTG, total IgA, and
IgG anti-deaminated gliadin peptide, and, if positive,
350
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can proceed to upper endoscopy with small bowel
biopsy. If the patient is on a gluten-free diet and their
serology tests are negative, they can be screened for
HLA-DQ2/DQ8 genes. If these genetic markers are
negative, it is very unlikely the patient has CD.5,19
However, a positive HLA-DQ2/DQ8 cannot be
used as a stand-alone test to reliably and deﬁnitively
diagnose CD.20
Endoscopy

If serology is positive, or if there is a high probability
of CD, patients should be referred to a gastroenterologist for an upper endoscopy and small bowel
biopsy. Samples obtained during endoscopy are
graded according to the Marsh criteria, which categorize the severity of the patchy, inﬂamed lesions of
the small bowel. Currently, debate exists regarding
other noninvasive approaches to conﬁrm CD, but
endoscopy with biopsy is considered the “gold
standard” for diagnosis.5,6
Alternative Testing for CD

Current trends include the use of alternative, lessinvasive methods to rule-out CD, especially for the
elderly and high-risk populations who may not
tolerate endoscopy. Capsule endoscopy, where an
encapsulated camera is ingested and passed through
the GI tract, may be ordered as an alternative if the
patient refuses endoscopy and no alarm symptoms are
present. However, it should be noted that the small
bowel capsule does not provide deﬁnitive histology
for diagnosis. Another option, although not the
preferred method, is to use a combination of antibody titers to predict the amount of damage caused
to the small intestine. Tortora et al18 found that the
presence of tTG levels (> 62.4 U/mL) accompanied
by elevated anti-endomysial antibody levels (> 45
U/mL) were diagnostic for small bowel damage.
CURRENT RECOMMENDATIONS FOR DIAGNOSING
IBS-D

Traditionally, there have been no speciﬁc tests that
directly detect IBS-D; the diagnosis has been assigned
only after ruling out other diseases.3 Essentially, the
patient’s speciﬁc clinical history and background
dictates the provider’s approach to testing. For cases
of chronic diarrhea (lasting longer than 2-4 weeks),
Volume 13, Issue 5, May 2017

the most basic serologic tests should include a
complete blood count, C-reactive protein, and CD
serology.16 Additional tests include stool studies, such
as cultures, ova and parasites, giardia, and/or
Clostridium difﬁcile, especially if the patient has
recently traveled abroad or has been hospitalized.2
Two new IBS-D diagnostic tools are now available to the NP: (1) the newly updated Rome IV
criteria; and (2) the IBSchekTM (Commonwealth
Laboratories LLC). The Rome IV criteria, introduced in May 2016, can be used to substantiate a
diagnosis IBS-D. The ROME IV includes questions
regarding the presence of recurrent abdominal pain
for at least 1 day/week in the last 3 months that is
associated with 2 or more of the following: defecation;
a change in frequency of stool; and a change in stool

consistency. A positive Rome IV screening has a
sensitivity of 62.7% and a 97.1% speciﬁcity.21 The
IBSchekTM was approved by the United States Food
and Drug Administration for use in 2015 and is an
enzyme-linked immunoassay‒based serum test that is
predictive of IBS-D based on the presence of 1 or 2
antibodies: anti‒cytolethal distending toxin B and
anti-vinculin.22 Currently, only 1 study has been
published regarding the accuracy of IBSchekTM.23
With elevated anti‒cytolethal distending toxin B, the
speciﬁcity and sensitivity for IBS-D are 91.6% and
43.7%, respectively. An elevated anti-viniculin is
83.8% speciﬁc and 32.6% sensitive for IBS-D.23
Because of the lack of data on IBSchekTM, some
researchers still recommend using symptom-based
criteria, such as the Rome IV, for diagnosis of IBS-D.24

Figure. Algorithm to differentiate LI, CD, and IBS-D.

Diarrhea
Are Alarm Symptoms Present?
(unintentional weight loss, rectal bleeding, family
history bowel/ovarian cancer, abdominal/rectal
masses, nighttime diarrhea, >60 yo)

No

Yes

Evaluate Accompanying Symptoms

Consider other differentials
diff
fferentials

Is there regular ingestion of gluten?

Eliminate dietary lactose 2 wks
Is patient compliant?

No
Consider other
differentials

Yes

No

Hydrogen Breath Test or
Lactose Tolerance Test
Negative

Positive

If symptoms
persist

Yes

Total IgA de icient

IgA tTG elevated;
elev
total IgA normal

Positive
(cannot be
used
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diagnose
CD)

Positive

*Negative

Consider other
differentials
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Suspect Irritable Bowel
Syndrome-D

Consider other
differentials

Key:
Consider other differentials and referral to
GI for further workup
** Without a gluten-rich diet CD cannot be
de initively diagnosed
% Systemic manifestations include iron
de iciency anemia, joint pain, osteoporosis,
migraines, depression, irritability,
epilepsy, vitamin de iciencies, proteincalorie malnutrition, dental enamel
defects, apthous stomatitis, dermatitis
herpetiformis
*

Suspect
Celiac

Positive
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*Negative

Suspect Lactose Intolerance

ROME IV criteria
and/or IBSchek TM
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Genetic
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DQ/DQ8

*Negative
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Yes
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**No
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DISCUSSION

Complaints of abdominal pain, bloating, gas, and
diarrhea are often present in LI, CD, and IBS-D and
contribute to a delay in diagnosis. For example,
ordering a series of stool studies is appropriate if the
patient has recently traveled internationally, recently
taken antibiotics, or has been hospitalized. Likewise,
when CD is the top differential, it is crucial that the
NP screens for a family history of CD and other
autoimmune diseases. When IBS-D is highly suspected, at the very least a complete blood count,
C-reactive protein, and CD serology should be
undertaken.
Limitations

There are limitations to our literature review, some
of which are attributable to the fact that a portion of
the information was gathered from studies performed
in other countries. LI, CD, and IBS-D each have an
effect on speciﬁc international populations, and
synthesizing data into 1 composition of evidence
could inﬂuence the results. Many of the studies that
were pertinent to LI involved patients of Asian
descent. The majority of these studies were performed on adults, 18-75 years old, so best practice
recommendations may not be as valuable in assisting
NPs in addressing GI issues in the pediatric
population.
CONCLUSION

LI, CD, and IBS-D present with similar symptoms,
which can be misleading and contribute to a delay in
diagnosis. The NP must be exceptionally thorough in
obtaining the patient’s history and performing the
physical exam in order to identify subtle clues that
could lead to the correct diagnosis. The patient’s age,
ethnicity, gender, family history, psychosocial history,
recent travel and hospitalization, diet, and timing of
symptoms should be considered. It is critical that
patients with alarm symptoms (fatigue, weight loss,
nocturnal diarrhea, and blood in the stool) are
referred to gastroenterology for more aggressive
testing, which likely involves endoscopy. The NP
can use the provided algorithm (see Figure) when he
or she encounters patients presenting with symptoms
of abdominal pain, bloating, gas, and diarrhea.
However, the NP should also consider other
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differentials and order additional testing that would
be appropriate for the individual’s presentation.
Therefore, it is critical for NPs to be prepared with a
process to distinguish bowel disorders, prioritize
differential diagnosis, and order appropriate tests
that can guide them in their diagnosis of LI, CD and
IBS-D with the goal of improving the quality of life
of patients.
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